Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) were up 3.1% during mid-day trading on Monday . The company traded as high as $6.08 and last traded at $6.07, with a volume of 607,940 shares changing hands. The stock had previously closed at $5.89.

A number of research firms recently weighed in on RPTP. FBR & Co reissued a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. Zacks Investment Research cut Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. Leerink Swann reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, April 12th. Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a research note on Monday, April 11th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $11.00.

The company’s market capitalization is $517.81 million. The company has a 50 day moving average price of $5.65 and a 200 day moving average price of $4.81.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of $27.47 million for the quarter, compared to the consensus estimate of $27.17 million. During the same quarter last year, the business posted ($0.24) earnings per share. Raptor Pharmaceutical Corp.’s revenue was up 34.3% on a year-over-year basis. On average, equities analysts expect that Raptor Pharmaceutical Corp. will post ($0.99) EPS for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. raised its position in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 as of its most recent filing with the SEC.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.